Sinopharm Group (1099.HK) Earnings Analysis

Sinopharm Group (1099.HK) next reports earnings on 2026-08-31, consensus EPS 1.26 HKD. Last quarter (2026-04-23) it beat with EPS 1.31 HKD vs 1.27 HKD est (+3.1%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E 6.39.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 1099.HK next report earnings?

Next earnings date2026-08-31
Consensus EPS estimate1.26 HKD
Revenue estimate329.05B

1099.HK earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-231.31 HKD1.27 HKD+3.1%Beat
2025-08-211.21 HKD1.06 HKD+14.2%Beat
2025-03-201.14 HKD1.5 HKD-24%Miss
2024-10-251.28 HKD1.48 HKD-13.5%Miss

Beat rate: 2/4 (50%) over reported quarters with consensus data.

1099.HK valuation and analyst view

Trailing P/E6.39
Trailing EPS2.285 HKD
Price / book0.54
Dividend yield4.67%
Market cap53.02B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Sinopharm Group (1099.HK)'s next earnings date?

Sinopharm Group is next scheduled to report on 2026-08-31, with a consensus EPS estimate of 1.26 HKD and revenue estimate of 329.05B.

Did 1099.HK beat earnings last quarter?

In its 2026-04-23 report, 1099.HK posted EPS of 1.31 HKD versus a 1.27 HKD estimate — a beat of 3.1%.

What is 1099.HK's earnings track record?

Over the last 4 reported quarters with consensus data, 1099.HK beat estimates 2 times (50%).

What is 1099.HK's current P/E ratio and EPS?

1099.HK trades at a trailing P/E of 6.39 on trailing EPS of 2.2847182862891433 HKD.

What do analysts rate 1099.HK?

1099.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.